27886041|t|Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria
27886041|a|In aim to achieve better infection control and possible eradication of the pathogens involved in chronic infections of patients with cystic fibrosis (CF) scientists have developed a new way to administer antimicrobials - inhalation. The first and so far the only available inhalable antimicrobial in Bulgaria is inhaled tobramycin (TOBI), introduced in 2009. We aimed to evaluate the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients before and after initiation of TOBI in the regular treatment regimen. We have determined the minimal inhibitory concentration (MIC) of 17 antimicrobials by the E-test (LIOFILCHEM) in sputa samples of 118 CF patients for the period of 2005-2014. The results were interpreted according to the annual Clinical and Laboratory Standards Institute guidelines. In the sputa of 70 patients a total of 102 P. aeruginosa isolates were found. Sixty-eight out of 102 (66.7%) were susceptible to all studied antimicrobials. We divided the isolates in two chronological groups: those collected before the introduction of TOBI as a regular treatment in 2009 and those collected after 2009. A significant reduction (p < 0,001-0,02) in susceptibility for the strains after 2009 was noted towards piperacillin (100% vs 50%), ceftazidime (100% / 77.3%), cefepime (97.9% / 68.2%), amikacin (100% / 63.6%), gentamicin (95.7% / 40.9%), tobramycin (93.6% / 59.1%) and ciprofloxacin (93.6% / 45.5%). The introduction of inhaled tobramycin as a regular therapy for CF patients in Bulgaria lead to a significant change in antimicrobial susceptibility of CF P. aeruginosa.
27886041	0	28	Antimicrobial susceptibility	T033	C0427965
27886041	32	54	Pseudomonas aeruginosa	T007	C0033809
27886041	55	61	before	T079	C0332152
27886041	66	71	after	T079	C0687676
27886041	72	82	initiation	T169	C1704686
27886041	86	104	inhaled tobramycin	T109,T195	C0723764
27886041	108	116	Bulgaria	T083	C0006368
27886041	142	159	infection control	T058	C0085557
27886041	173	184	eradication	T058	C3178994
27886041	192	201	pathogens	T001	C0450254
27886041	202	210	involved	T169	C1314939
27886041	214	232	chronic infections	T047	C0151317
27886041	236	244	patients	T101	C0030705
27886041	250	265	cystic fibrosis	T047	C0010674
27886041	267	269	CF	T047	C0010674
27886041	271	281	scientists	T097	C0402112
27886041	310	320	administer	T169	C1621583
27886041	321	335	antimicrobials	T195	C0003232
27886041	338	348	inhalation	T169	C0205535
27886041	390	399	inhalable	T040	C0004048
27886041	400	413	antimicrobial	T195	C0003232
27886041	417	425	Bulgaria	T083	C0006368
27886041	429	447	inhaled tobramycin	T109,T195	C0723764
27886041	449	453	TOBI	T109,T195	C0723764
27886041	488	496	evaluate	T058	C0220825
27886041	501	529	antimicrobial susceptibility	T033	C0427965
27886041	533	555	Pseudomonas aeruginosa	T007	C0033809
27886041	556	564	isolates	T123	C3494793
27886041	570	585	cystic fibrosis	T047	C0010674
27886041	587	589	CF	T047	C0010674
27886041	591	599	patients	T101	C0030705
27886041	600	606	before	T079	C0332152
27886041	611	616	after	T079	C0687676
27886041	617	627	initiation	T169	C1704686
27886041	631	635	TOBI	T109,T195	C0723764
27886041	643	650	regular	T080	C0205272
27886041	651	668	treatment regimen	T061	C0040808
27886041	693	725	minimal inhibitory concentration	T059	C0427978
27886041	727	730	MIC	T059	C0427978
27886041	738	752	antimicrobials	T195	C0003232
27886041	760	766	E-test	T060	C1275991
27886041	783	796	sputa samples	T031	C0444159
27886041	804	806	CF	T047	C0010674
27886041	807	815	patients	T101	C0030705
27886041	824	830	period	T079	C1948053
27886041	862	873	interpreted	T169	C1285553
27886041	891	952	annual Clinical and Laboratory Standards Institute guidelines	T170	C0282574
27886041	961	966	sputa	T031	C0038056
27886041	973	981	patients	T101	C0030705
27886041	997	1010	P. aeruginosa	T007	C0033809
27886041	1011	1019	isolates	T123	C3494793
27886041	1068	1079	susceptible	T169	C0231204
27886041	1095	1109	antimicrobials	T195	C0003232
27886041	1126	1134	isolates	T123	C3494793
27886041	1142	1155	chronological	T170	C0008717
27886041	1156	1162	groups	T078	C0441833
27886041	1170	1179	collected	T169	C1516698
27886041	1180	1186	before	T079	C0332152
27886041	1191	1203	introduction	T169	C0579004
27886041	1207	1211	TOBI	T109,T195	C0723764
27886041	1217	1224	regular	T080	C0205272
27886041	1225	1234	treatment	T169	C0039798
27886041	1253	1262	collected	T169	C1516698
27886041	1263	1268	after	T079	C0687676
27886041	1277	1288	significant	T078	C0750502
27886041	1289	1298	reduction	T080	C0392756
27886041	1319	1333	susceptibility	T169	C1264642
27886041	1342	1349	strains	T001	C1518614
27886041	1350	1355	after	T079	C0687676
27886041	1379	1391	piperacillin	T109,T195	C0031955
27886041	1407	1418	ceftazidime	T109,T195	C0007559
27886041	1435	1443	cefepime	T109,T195	C0055003
27886041	1461	1469	amikacin	T109,T195	C0002499
27886041	1486	1496	gentamicin	T109,T195	C3854019
27886041	1514	1524	tobramycin	T109,T195	C0040341
27886041	1545	1558	ciprofloxacin	T109,T121	C0008809
27886041	1596	1614	inhaled tobramycin	T109,T195	C0723764
27886041	1628	1635	therapy	T061	C0087111
27886041	1640	1642	CF	T047	C0010674
27886041	1643	1651	patients	T101	C0030705
27886041	1655	1663	Bulgaria	T083	C0006368
27886041	1674	1685	significant	T078	C0750502
27886041	1686	1692	change	T081	C0443172
27886041	1696	1724	antimicrobial susceptibility	T033	C0427965
27886041	1728	1730	CF	T047	C0010674
27886041	1731	1744	P. aeruginosa	T007	C0033809